Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed a clinical trial evaluating casimersen or golodirsen, per protocol.~* Is between 7 and 23 years of age, inclusive, at enrollment.~Other inclusion/exclusion criteria apply.

- Gender: MALE
- Minimum Age: 7 Years
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- Casimersen (Type: EXPERIMENTAL): Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
- Golodirsen (Type: EXPERIMENTAL): Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).